SpyGlass Pharma (SGP) Stock Statistics & Valuation Metrics

SpyGlass Pharma has a market cap or net worth of ―. The enterprise value is $459.46M.

SpyGlass Pharma has 33,433,353 shares outstanding. The number of shares has decreased by -2.65% in one year.

SpyGlass Pharma’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is -38.64%.

The current PE Ratio of SpyGlass Pharma is ―. SpyGlass Pharma’s PEG ratio is 0.00.

In the last 12 months, SpyGlass Pharma had revenue of 0.00 and earned -39.87M in profits. Earnings per share was -1.19.

In the last 12 months, operating cash flow was -22.88M and capital expenditures -1.10M, giving a free cash flow of -23.97M billion.

SpyGlass Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

SpyGlass Pharma upcoming earnings date is May 14, 2026, After Close (Confirmed).

SpyGlass Pharma as a current ratio of 12.67, with Debt / Equity ratio of 0.64%

In the past 12 months, SpyGlass Pharma has paid 0.00 in taxes.

SpyGlass Pharma EV to EBITDA ratio is -19.29, with an EV/FCF ratio of -23.52.

SpyGlass Pharma has $251.00M in cash and marketable securities with $1.61M in debt, giving a net cash position of $249.40M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for SpyGlass Pharma is $45.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy